Mr. Rob Carducci reports

GLOW LIFETECH REDUCES OVER 41 MILLION WARRANTS AND 5 MILLION OPTIONS, STRENGTHENING CAPITAL STRUCTURE; ALL $0.05 WARRANTS NOW EXPIRED

Glow Lifetech Corp. made a significant reduction in its outstanding share purchase warrants and stock options during the first quarter of 2026, marking an important milestone in the company's continuing efforts to further simplify its capital structure and reduce potential dilution.

Significant reduction in warrant and option overhang

During Q1 2026, the company reduced a total of 41,031,673 share purchase warrants and 5,025,000 stock options, building on a series of previous balance sheet improvements in 2025. Of the warrants, 30,123,371 (76 per cent) expired unexercised and all 5,025,000 stock options expired unexercised, significantly minimizing potential dilution.

In addition, 10,908,302 warrants were exercised, for total proceeds of $542,415 to the company, further strengthening its already-strong balance sheet. The majority of these exercises, representing approximately 89 per cent, were completed by management, directors and long-term strategic shareholders, reflecting strong alignment and continued confidence in the company's long-term growth strategy.

Strengthening capital structure and shareholder alignment

Over the trailing 12 months, Glow has reduced its fully diluted share count by approximately 16.6 per cent, driven by the expiry of warrants and stock options, demonstrating a continued focus on disciplined capital structure management. The combination of warrant expiry and exercise represents a meaningful step in simplifying the company's capital structure and improving overall equity quality.

"This significant reduction in our warrant and option overhang marks an important milestone for Glow and reflects our continued focus on disciplined capital and financial management," said Rob Carducci, chief executive officer of Glow Lifetech. "The participation from management, directors and long-term shareholders in warrant exercises further demonstrates strong alignment and confidence in our strategy. With a cleaner capital structure, a strengthened financial position and continued commercial momentum, we are well positioned to advance into our next phase of growth."

Advancing a stronger financial foundation

The reduction in outstanding warrants and options builds on a series of recent balance sheet improvements, including the company's achievement of debt-free status and its first positive cash flow from operations. Together, these milestones reinforce Glow's strengthening financial foundation and support its ability to execute its growth strategy with increased flexibility and discipline.

As the company continues to build on its commercial progress and expand its national footprint, it remains focused on maintaining capital efficiency, strengthening operating fundamentals and delivering long-term sustainable value for shareholders.

About Glow Lifetech Corp.

Glow Lifetech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has a groundbreaking, plant-based MyCell technology delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of the valuable compounds.

We seek Safe Harbor.